SISI News & Events

Shineco subsidiary, Xi'an Dong'ao Health Management has signed a technology services contract valued at $8.7M with Xinke Future Biotechnology for the research and development of "microalgae-derived extracellular vesicles" technology. Separately, a delegation from Singapore's biotechnology company, BICC, completed a productive site visit to Dong'ao Health on September 10. The parties reached a broad consensus on key collaboration areas, including establishing a joint laboratory and a technology exchange mechanism, marking a substantive step forward in Shineco's "technology industrialization and global synergy" strategy in the biocellular field. As the core entity executing Shineco's strategy in the biocellular market, Dong'ao Health's new contract focuses on cutting-edge microalgae-derived extracellular vesicles technology. The service period runs from August 25, 2025, to December 31, 2026, with the goal of building a comprehensive, end-to-end R&D system from basic research to process development and product translation. Specific tasks include functional validation during the basic research phase; breaking bottlenecks in large-scale separation and extraction processes to achieve mass production; and developing at least two therapeutic products with full regulatory support to effectively transition the technology from the lab to the market. The total value of $8.7M will be paid in phases, with an initial payment of $560,000 already received. Subsequent payments are tied to R&D milestones, ensuring stable revenue recognition and creating long-term profit growth drivers through the "develop once, deploy multiple times" nature of the technology. Concurrent with this R&D progress, Shineco's international cooperation achieved a key milestone. BICC sent a high-level delegation to Dong'ao Health from September 6-10, including Chairman Yang Shengnan, CEO Barbara Tan, CFO Jon Lim, Chief Scientist Chen Yanming, and shareholder Chen Laifu. The delegation conducted on-site inspections of Dong'ao Health's four core segments-the Health and Wellness Center, Cell R&D Center, under-construction Alzheimer's Disease Care Town, and partner "Anhe Meige Medical Aesthetic Hospital"-to evaluate potential synergies. The parties agreed to establish a joint laboratory, implement a technology exchange mechanism, integrate BICC's network of over 3,000 agents in Southeast Asia with Dong'ao Health's domestic wellness channels, and co-establish stem cell transfusion centers to promote standardized clinical services.

Shineco announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production of high-purity, highly active free-form soybean phospholipids. This breakthrough was made possible through its proprietary APCC-UF pure physical extraction technology, overcoming a persistent global technical challenge in the field. Testing by multiple authoritative institutions confirms that the product's key metrics meet internationally leading standards, providing robust technical support for the global upgrade of the natural active phospholipid industry. Analysts suggest that Shineco's technological breakthrough possesses significant scarcity value and commercial potential, likely to transform the company's business structure and enhance its overall gross margin and valuation. Investors are advised to monitor closely the progress of capacity rollout, downstream customer partnerships, and international market access.

Shineco has entered into a strategic cooperation agreement with Singapore-based BICC to jointly promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase of "cross-enterprise redeemability" for cell assets on the blockchain, advancing the RWA ecosystem from "technical on-chain integration" to "real-world application. This partnership builds on Shineco's prior initiatives: establishing a Cell Digital Division, signing an agreement with Plus Me Limited for on-chain cell asset management and marketing ecosystems, and acquiring a 51% stake in Xi'an Dong'ao Health Management. The two parties will collaborate on standard-setting, compliance coordination, and scenario exploration to transition the project from "technical feasibility" to "verifiable applicability."Under the cooperation framework, Plus Me will provide full-lifecycle digital management for Shineco's compliant mesenchymal stem cells on the Ethereum mainnet, generating"digital identities" and issuing ERC-1400/ERC-20 standard "Cell Reimbursement Vouchers." Following the collaboration with BICC, BICC's iPSC stem cell storage services will be integrated into Shineco's blockchain system. Users holding" Cell Reimbursement Vouchers" will be able to redeem them in designated BICC scenarios, forming a cross-enterprise service

Shineco announced the execution of a "Cellular Asset On-Chaining and Marketing Ecosystem Cooperation Agreement" with blockchain infrastructure provider Plus Me Limited. This partnership enables blockchain-based tokenization of biological cellular assets, facilitating global transfers and auditable standardized custody, creating an 'Asset On-Chaining + Application Scenarios' model in cell therapy. Under the agreement, Plus Me will deploy full lifecycle digital custody of Shineco's compliant mesenchymal stem cells on the Ethereum mainnet. Smart contracts will immutably secure asset ownership rights, issuing non-fungible digital identifiers for each cellular asset to ensure traceability and compliance. Verifiable uniqueness and regulatory compliance are cryptographically enforced through on-chain hashing. Shineco has secured a controlling 51% stake in Xi'an Dong'ao Health Management, a specialist in cryogenic cell storage and clinical applications, provides the off-chain infrastructure critical to token redemption, as of August 18.